Clover Biopharmaceuticals Begins Phase I Trials for New RSV and hMPV Vaccine Candidates Clover Biopharmaceuticals has launched a Phase I clinical trial for SCB-1022 and SCB-1033, a promising combination vaccine for RSV, hMPV, and PIV3 aimed at addressing respiratory diseases.

Clover Biopharmaceuticals Begins Phase I Trials for New RSV and hMPV Vaccine Candidates #China #Shanghai #RSV_Vaccine #Clover_Biopharma #Phase_I_Trials